CXCR4 and glioblastoma: This is in contrast with findings by Kamatani et al. where CXCR4 immunoreactivity was observed in 24 of 24 (100%) glioblastomas, 9 of 9 (100%) anaplastic astrocytomas and 10 of 11 (91%) astrocytomas or oligoastrocytomas [37].